The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Wiley Matthew T. since 2019.
This trader's CIK number is 1759703.
At the time of last reporting, Wiley Matthew T. was the Chief Commercial Officer of Definium Therapeutics, Inc.. (stock ticker symbol DFTX).
Also see all insider trading activities at Definium Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | FOMX | 13,440 | $50,534 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | BTAI | 0 | $0 | 7,739 | $6,561 | 4,500 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | DFTX | 0 | $0 | 2,867 | $129,101 | 0 | $0 |
1. Foamix Pharmaceuticals Ltd. (FOMX)
2. Bioxcel Therapeutics, Inc. (BTAI)
3. Definium Therapeutics, Inc. (DFTX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-03-05 | FOMX | Buy | 13,440 | 3.76 | 50,534 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-10-03 | BTAI | Sale | 6,272 | .55 | 3,449 |
| 2024-09-16 | BTAI | Sale | 215 | .69 | 148 |
| 2024-09-15 | BTAI | Option Ex | 750 | .00 | 0 |
| 2024-06-17 | BTAI | Sale | 244 | 1.26 | 308 |
| 2024-06-15 | BTAI | Option Ex | 750 | .00 | 0 |
| 2024-04-04 | BTAI | Sale | 1,008 | 2.63 | 2,656 |
| 2024-03-15 | BTAI | Option Ex | 3,000 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-25 | DFTX | Sale | 2,867 | 45.03 | 129,101 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wiley Matthew T. (Chief Commercial Officer of Definium Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.